Acelyrin (NASDAQ:SLRN) Price Target Raised to $8.00 at HC Wainwright

Acelyrin (NASDAQ:SLRN) had its price objective boosted by HC Wainwright from $6.00 to $8.00 in a report issued on Thursday morning,Benzinga reports. HC Wainwright currently has a neutral rating on the stock.

SLRN has been the subject of several other research reports. Morgan Stanley lowered their price objective on shares of Acelyrin from $13.00 to $6.00 and set an “equal weight” rating for the company in a research note on Monday, August 19th. Piper Sandler decreased their price target on shares of Acelyrin from $68.00 to $20.00 and set an “overweight” rating for the company in a research report on Wednesday, August 14th. Finally, Wells Fargo & Company upped their price objective on Acelyrin from $13.00 to $15.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 16th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Acelyrin presently has an average rating of “Moderate Buy” and a consensus price target of $11.50.

Acelyrin Trading Down 9.1 %

SLRN stock opened at $4.69 on Thursday. The business’s fifty day moving average price is $5.41 and its 200 day moving average price is $5.02. Acelyrin has a 12-month low of $3.36 and a 12-month high of $9.20. The company has a market capitalization of $470.55 million, a PE ratio of -1.91 and a beta of 1.98.

Institutional Trading of Acelyrin

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. lifted its stake in Acelyrin by 118.0% in the first quarter. Ameritas Investment Partners Inc. now owns 7,243 shares of the company’s stock valued at $49,000 after buying an additional 3,921 shares during the last quarter. HighTower Advisors LLC purchased a new position in shares of Acelyrin in the 3rd quarter valued at approximately $50,000. Principal Financial Group Inc. acquired a new position in shares of Acelyrin in the second quarter valued at approximately $49,000. SG Americas Securities LLC purchased a new stake in shares of Acelyrin during the second quarter worth approximately $51,000. Finally, Nisa Investment Advisors LLC grew its position in Acelyrin by 58,570.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 14,081 shares of the company’s stock valued at $62,000 after buying an additional 14,057 shares during the last quarter. Institutional investors and hedge funds own 87.31% of the company’s stock.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.